Whole bills for providers from the Normal Healthcare System (GHS) in Cyprus got here to €1.21 billion in 2021, from roughly 920,000 beneficiaries, Senior Officer of the Well being Insurance coverage Organisation (HIO) Angelos Tropis instructed CNA, including that primarily based on the preliminary outcomes, the 2021 bills will roughly be equal to complete income.
He mentioned that regardless of the unfavourable circumstances, the organisation has managed to create a surplus of €300mn which might cowl any marginal deficits that may happen and which ensures the Fund’s sustainability for the approaching years.
For 2021, mentioned Tropis expenditure for well being providers for about 920,000 beneficiaries amounted to €1.21 billion, of which €227mn involved outpatient providers by specialist docs, €87.7mn for private docs, €53.5mn for laboratory charges, €32.7mn for pharmacists` charges, €36.7mn for charges of different well being professionals (physiotherapists, dentists and others), whereas the price for outpatient prescription drugs amounted to €180mn.
He additionally mentioned expenditure for in-patient remedy in 2021 got here to €563mn whereas bills for First Assist and ambulances stood at €32.4mn.
Relating to income from contributions for the primary ten months of 2021 (January – October), due to a two-month delay in gathering the information, mentioned Tropis these amounted to €935.3mn, whereas income for the entire of final yr from co-payments and contributions amounted to €45.1mn.
So far as the 2022 Funds is worried, Tropis instructed CNA that it “has been adjusted primarily based on the suggestions of the Ministry of Finance”. He defined, the state contribution, which was included within the unique draft, totaling €55mn was eliminated, of which €30 million, has been eliminated.
Expenditure has been balanced with income and changes have been made in relation to the job vacancies, he underlined.
For 2022, income is estimated at €1.39bn which incorporates the GHS and administrative income in addition to expenditure totaling €1.38bn which incorporates GHS expenditure in addition to the HIO growth expenditure.
The brand new price range has been resubmitted and is predicted to be permitted by the Home of Representatives.